These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21821879)

  • 1. In silico identification and crystal structure validation of caspase-3 inhibitors without a P1 aspartic acid moiety.
    Ganesan R; Jelakovic S; Mittl PR; Caflisch A; Grütter MG
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Aug; 67(Pt 8):842-50. PubMed ID: 21821879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1.
    Rotonda J; Garcia-Calvo M; Bull HG; Geissler WM; McKeever BM; Willoughby CA; Thornberry NA; Becker JW
    Chem Biol; 2001 Apr; 8(4):357-68. PubMed ID: 11325591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.
    Choong IC; Lew W; Lee D; Pham P; Burdett MT; Lam JW; Wiesmann C; Luong TN; Fahr B; DeLano WL; McDowell RS; Allen DA; Erlanson DA; Gordon EM; O'Brien T
    J Med Chem; 2002 Nov; 45(23):5005-22. PubMed ID: 12408711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors.
    Ganesan R; Jelakovic S; Campbell AJ; Li ZZ; Asgian JL; Powers JC; Grütter MG
    Biochemistry; 2006 Aug; 45(30):9059-67. PubMed ID: 16866351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational restrictions in the active site of unliganded human caspase-3.
    Ni CZ; Li C; Wu JC; Spada AP; Ely KR
    J Mol Recognit; 2003; 16(3):121-4. PubMed ID: 12833566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
    Lockbaum GJ; Leidner F; Rusere LN; Henes M; Kosovrasti K; Nachum GS; Nalivaika EA; Ali A; Yilmaz NK; Schiffer CA
    ACS Infect Dis; 2019 Feb; 5(2):316-325. PubMed ID: 30543749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase-3 binds diverse P4 residues in peptides as revealed by crystallography and structural modeling.
    Fang B; Fu G; Agniswamy J; Harrison RW; Weber IT
    Apoptosis; 2009 May; 14(5):741-52. PubMed ID: 19283487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of aspergillopepsin I from Aspergillus phoenicis: variations of the S1'-S2 subsite in aspartic proteinases.
    Cho SW; Kim N; Choi MU; Shin W
    Acta Crystallogr D Biol Crystallogr; 2001 Jul; 57(Pt 7):948-56. PubMed ID: 11418762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
    J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
    J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY; Sall DJ; Briggs SL; Clawson DK; Zhang M; Smith GF; Schevitz RW
    Protein Sci; 2000 Jan; 9(1):29-36. PubMed ID: 10739244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
    Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
    Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality.
    Lee D; Long SA; Adams JL; Chan G; Vaidya KS; Francis TA; Kikly K; Winkler JD; Sung CM; Debouck C; Richardson S; Levy MA; DeWolf WE; Keller PM; Tomaszek T; Head MS; Ryan MD; Haltiwanger RC; Liang PH; Janson CA; McDevitt PJ; Johanson K; Concha NO; Chan W; Abdel-Meguid SS; Badger AM; Lark MW; Nadeau DP; Suva LJ; Gowen M; Nuttall ME
    J Biol Chem; 2000 May; 275(21):16007-14. PubMed ID: 10821855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding.
    Romanowski MJ; Scheer JM; O'Brien T; McDowell RS
    Structure; 2004 Aug; 12(8):1361-71. PubMed ID: 15296730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
    Fjellström O; Akkaya S; Beisel HG; Eriksson PO; Erixon K; Gustafsson D; Jurva U; Kang D; Karis D; Knecht W; Nerme V; Nilsson I; Olsson T; Redzic A; Roth R; Sandmark J; Tigerström A; Öster L
    PLoS One; 2015; 10(1):e0113705. PubMed ID: 25629509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
    Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR
    Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
    Steuber H; Heine A; Klebe G
    J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue.
    Estébanez-Perpiña E; Fuentes-Prior P; Belorgey D; Braun M; Kiefersauer R; Maskos K; Huber R; Rubin H; Bode W
    Biol Chem; 2000 Dec; 381(12):1203-14. PubMed ID: 11209755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the tertiary structure of a caspase-9/inhibitor complex.
    Chou KC; Tomasselli AG; Heinrikson RL
    FEBS Lett; 2000 Mar; 470(3):249-56. PubMed ID: 10745077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.